Since the approval of ipilimumab in 2011 and the subsequent approvals of pembrolizumab and nivolumab, immuno-oncology has become a pivotal approach in the development of innovative therapeutics. Despite the use of conventional tissue/protein biomarkers such as PD-L1 measured by immunohistochemistry, the identification of patient populations who can best benefit from the treatment has proven less straightforward than anticipated. To better predict patients likely to respond to immuno-therapeutics, biomarker evaluation has expanded to the use of molecular analysis and has evolved from a focus on single analyte biomarker testing to multiplex analysis, wherein multiple genes to whole exomes can be assessed.
Today, a variety of treatment modalities targeting the immune system require tailored broad-spectrum biomarker screening to characterize mutational changes and the effects they have on the ability of T cells to mount immune responses to tumor antigens. Beyond evaluating features of the tumor itself, parallel characterization of immune features within the tumor microenvironment is critical for biomarker development in immuno-oncology.
Authors:
Victor Weigman, Ph.D., Associate Director, Translational Genomics, IQVIA Laboratories
Patrick Hurban, Ph.D., Scientific Advisor, Genomics; Senior Director and Global Head, Translational Genomics, IQVIA Laboratories
Alan Wookey, B.Sc., Scientific Advisor, Oncology, Q2 Solutions
Patrice Hugo, Ph.D., Chief Scientific Officer, IQVIA Laboratories
Complete the form below to access this insight brief
Related Insights
Reproducibility Challenges in an era of Massive Data
Presented at the MCBIOS & MAQC 2021 Joint Conference
A Verified Genomic Reference Sample for Assessing Performance of Cancer Panels Detecting Small Variants of Low Allele Frequency
Presented at the MCBIOS & MAQC 2021 Joint Conference
Unexpected Impacts to Library Complexity After DNA and RNA Library Preparation in Illumina Next Generation Sequencing
Presented at the MCBIOS & MAQC 2021 Joint Conference
Immune Landscape Signatures for Characterization of Tumor Microenvironment and Response to Therapy
Gene expression and analysis for detection of 38 Immune Landscape Signatures
Using Gene Signature Methodologies to Strengthen Immuno-Oncology Trials
Genomic technologies that empower and enhance immuno-oncology trials
Laboratory Solutions for Hepatitis B (HBV) Clinical Trials
Insight brief by Joseph Sebastian, Ph.D., Scientific Advisor, Infectious & Liver Diseases
Enabling blood sample prep for single cell sequencing in clinical research
The Role of Genomics in Clinical Trials with Patrick Hurban
I-O clinical development podcast series
IQVIA Laboratories Corporate Brochure
A global drug discovery and development laboratory services organization
Evaluating and Implementing SARS-CoV-2 PCR Tests for Diagnostic and Clinical Trial Use
AAPS 2020 COVID-19 Workshop: Current Pharmaceutical Developments for Cures and Prevention
